Related Experiment Video
Updated: Aug 18, 2026
Intraluminal Drug Delivery to the Mouse Arteriovenous Fistula Endothelium
Published on: March 4, 2016
E2F decoy oligodeoxynucleotides on neointimal hyperplasia in canine vein graft
1Department of Surgery, Institute for Medical Science, Keimyung University, Daegu, Korea. wh51cho@dsmc.or.kr
Abstract:
Double-stranded DNA with high affinity to E2F as a decoy cis-element blocks the activation of genes mediating the cell cycle, resulting in effective suppression of the smooth muscle cell proliferation that causes intimal hyperplasia. To evaluate the effect of the E2F decoy to suppress neointimal hyperplasia autogenous venous bypass grafts were performed in dogs after incubation with heparin (group 1), with E2F decoy oligodeoxynucleotides (ODN) (groups 2 and 3), or with a random ODN (group 4) using a Japan-liposomeal method based on a hemagglutinating virus. The intimal and medial cross-sectional surface area of the anastomotic site was measured at 4 months after bypass surgery in groups 1, 3, and 4 by computerized planimetry and at 4 weeks in group 2 to compare the intimal/medial (I/M) area ratios. Autogenous vein grafts treated with E2F decoy showed a significant reduction in I/M area ratio (0.26 +/- 0.11) compared with the heparin-treated control group (1.49 +/- 0.29) or the mismatched ODN-treated group (1.61 +/- 0.28; P = .000). There was no difference in the I/M area ratio according to experimental periods (groups 2 vs 3: 0.26 +/- 0.11 vs 0.37 +/- 0.32; P = .446) or the anastomotic sites (proximal vs distal; P = .934). In conclusion, an E2F decoy can suppress neointimal hyperplasia in autogenous vein grafts, which may prolong patency by reducing graft stenosis.
Insights
E2F decoy DNA effectively suppresses smooth muscle cell proliferation, significantly reducing intimal hyperplasia in vein grafts. This approach may improve graft patency by preventing stenosis.
Area of Science:
- Vascular Biology
- Molecular Biology
- Surgical Innovation
Background:
- Intimal hyperplasia is a major cause of vein graft failure.
- Smooth muscle cell proliferation drives intimal hyperplasia.
- E2F transcription factors regulate cell cycle genes critical for proliferation.
Purpose of the Study:
- To investigate the efficacy of E2F decoy oligodeoxynucleotides (ODN) in suppressing neointimal hyperplasia.
- To evaluate the impact of E2F decoy on vein graft patency.
Main Methods:
- Autogenous venous bypass grafts were created in dogs.
- Grafts were treated with E2F decoy ODN, heparin, or random ODN.
- Intimal and medial cross-sectional areas were measured using computerized planimetry.
Main Results:
- E2F decoy treatment significantly reduced the intimal/medial (I/M) area ratio compared to controls (0.26 vs. 1.49 or 1.61, P=.000).
- No significant difference in I/M ratio was observed between experimental periods or anastomotic sites.
- E2F decoy demonstrated potent suppression of neointimal hyperplasia.
Conclusions:
- E2F decoy is effective in suppressing neointimal hyperplasia in autogenous vein grafts.
- This strategy holds potential for prolonging graft patency by reducing stenosis.
- E2F decoy represents a promising therapeutic target for preventing graft failure.
